BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

The FDA’s clearance of this expanded label enables access to Deep TMS™ for the critically important adolescent patient ...